Goldman Sachs
RBOT

Goldman Sachs’s Vicarious Surgical RBOT Stock Holding History

Goldman Sachs’s Portfolio RBOT Stock Details RBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,658
Closed -$15K – 5871
2024
Q1 		$15K Buy
1,658
+305
+23% +$3.64K ﹤0.01% 5414
2023
Q4 		$14.9K Sell
1,353
-203
-13% -$2.26K ﹤0.01% 5462
2023
Q3 		$27.6K Sell
1,556
-818
-34% -$29.8K ﹤0.01% 5330
2023
Q2 		$130K Buy
2,374
+269
+13% +$17.1K ﹤0.01% 5307
2023
Q1 		$143K Buy
2,105
+606
+40% +$47.1K ﹤0.01% 5395
2022
Q4 		$90.8K Buy
1,499
+304
+25% +$28.3K ﹤0.01% 5503
2022
Q3 		$120K Sell
1,195
-700
-37% -$81.6K ﹤0.01% 5642
2022
Q2 		$167K Buy
1,895
+1,124
+146% +$137K ﹤0.01% 5702
2022
Q1 		$117K Buy
771
+360
+88% +$67K ﹤0.01% 6057
2021
Q4 		$131K Buy
+411
New +$145K ﹤0.01% 6055
2021
Q3 		– Sell
-9,078
Closed -$2.71M – 6461
2021
Q2 		$2.71M Sell
9,078
-5,255
-37% -$1.57M ﹤0.01% 3926
2021
Q1 		$4.27M Buy
14,333
+1,666
+13% +$510K ﹤0.01% 3269
2020
Q4 		$3.86M Buy
+12,667
New +$3.72M ﹤0.01% 3207

Other funds holding RBOT

VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
DP
DDD Partners Bellevue, Washington $1.45B AUM 9.14% 1-Year Est. Return
MAMHA
MY.Alpha Management HK Advisors Hong Kong $246M AUM 73.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AMH
Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs's RBOT Position: Q2 2024 in Review

Goldman Sachs sold out of Vicarious Surgical (RBOT) in Q2 2024, closing a stake of 1,658 shares — an estimated $15K sold.

Goldman Sachs first reported a position in RBOT in Q4 2020 and held it in 13 quarters. The position peaked at $4.27M in Q1 2021. 38 funds tracked by Wall St. Rank hold RBOT as of Q2 2024.

  • Goldman Sachs reported no remaining Vicarious Surgical position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,658 Vicarious Surgical shares in Q2 2024, an estimated $15K.
  • Goldman Sachs first reported a position in Vicarious Surgical in Q4 2020 and held it in 13 quarters.
  • Goldman Sachs's Vicarious Surgical position peaked at $4.27M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Vicarious Surgical as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.